Harmony Biosciences Files 8-K on Financials

TL;DR

Harmony Biosciences dropped an 8-K on Oct 23rd detailing their financial condition. Check it out.

AI Summary

Harmony Biosciences Holdings, Inc. filed an 8-K on October 23, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462. The company is incorporated in Delaware and operates in the Pharmaceutical Preparations industry.

Why It Matters

This 8-K filing provides crucial updates on Harmony Biosciences' financial performance and condition, which is essential for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting financial information and does not appear to contain any significant new risks or negative developments.

Key Players & Entities

• Harmony Biosciences Holdings, Inc. (company) — Registrant
• October 23, 2025 (date) — Date of report
• 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462 (address) — Principal executive offices
• Delaware (jurisdiction) — State of incorporation
• 2834 (sic_code) — Standard Industrial Classification for Pharmaceutical Preparations

FAQ

Key Financial Figures

• $0.00001 — ) on which registered Common Stock, $0.00001 par value per share HRMY The Nasdaq

Filing Documents

• hrmy-20251023x8k.htm (8-K) — 43KB
• hrmy-20251023xex99d1.htm (EX-99.1) — 57KB
• hrmy-20251023x8k001.jpg (GRAPHIC) — 1KB
• hrmy-20251023xex99d1001.jpg (GRAPHIC) — 11KB
• 0001104659-25-101688.txt ( ) — 238KB
• hrmy-20251023.xsd (EX-101.SCH) — 3KB
• hrmy-20251023_lab.xml (EX-101.LAB) — 16KB
• hrmy-20251023_pre.xml (EX-101.PRE) — 10KB
• hrmy-20251023x8k_htm.xml (XML) — 5KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On October 23, 2025, Harmony Biosciences Holdings, Inc. (the "Company") issued a press release announcing its preliminary net product revenue for the third quarter of 2025. In addition, the Company provided updated guidance related to 2025 net product revenue. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference . Note Regarding Forward-Looking Statements Certain statements in this Current Report on Form 8-K constitute "forward-looking statements" within the meaning of the federal securities laws. These statements are based on management's current opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results. These forward looking statements are only predictions, not historical fact, and involve certain risks and uncertainties, as well as assumptions. Actual results, levels of activity, performance, achievements and events could differ materially from those stated, anticipated or implied by such forward-looking statements. While the Company believes that its assumptions are reasonable, it is very difficult to predict the impact of known factors, and, of course, it is impossible to anticipate all factors that could affect actual results. There are many risks and uncertainties that could cause actual results to differ materially from the forward-looking statements made herein including the risks discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission ("SEC,") on February 25, 2025, as well as other factors described from time to time in the Company's filings with the SEC. Such forward-looking statements are made only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to publicly update or revise any forward-

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1* Press release issued by the Company, dated October 23, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * This Exhibit is furnished herewith and will not be deemed "filed" for purposes of Section 18 of the Exchange Act or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act except to the extent that Harmony Biosciences Holdings, Inc. specifically incorporates it by reference.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HARMONY BIOSCIENCES HOLDINGS, INC. Date: October 23, 2025 By: /s/ Sandip Kapadia Sandip Kapadia Chief Financial Officer and Chief Administrative Officer

View Full Filing

View this 8-K filing on SEC EDGAR